Articles - GLP1 drugs changing weight loss and Life & Health insurance


Weight-loss injectables like Wegovy or Ozempic are gaining popularity amid an escalating global obesity crisis. Since 1975, worldwide obesity rates have nearly tripled, with projections indicating that over half of the global population will be overweight or obese by 2035. John Schoonbee, Global Chief Medical Officer, and Adam Strange, Life & Health R&D Manager, elaborate on the impact of GLP-1 drugs on weight loss, metabolic health and insurance. These medications influence risk factors such as insulin resistance, cardiovascular disease, and cancer. Additionally, they discuss the implications of these drugs on Life & Health insurance, including life, critical illness, and disability income, as well as future underwriting risk assessments.

 

Back to Index


Similar News to this Story

The future of income investing: Taking a portfolio approach
Income investing has traditionally been associated with a narrow range of assets, but is that approach still fit for purpose? Sophie Tennison is joine
Make your nominations now for the 2026 Actuarial Post Awards
We are pleased to announce that the nominations for the Actuarial Post Awards 2026 are now open! This will be the 14th year of running the awards and
Salary sacrifice changes in 2029
HMRC estimates that nearly 7.7 million employees in the UK currently use salary sacrifice to make pension contributions. With many benefitting from th

Site Search

Exact   Any  

Latest Actuarial Jobs

Actuarial Login

Email
Password
 Jobseeker    Client
Reminder Logon

APA Sponsors

Actuarial Jobs & News Feeds

Jobs RSS News RSS

WikiActuary

Be the first to contribute to our definitive actuarial reference forum. Built by actuaries for actuaries.